Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40168 |
DHODH-IN-16
|
Dehydrogenase | Metabolism |
DHODH-IN-16 是一种有效的二氢乳清酸脱氢酶抑制剂(DHODH,IC50 = 0.396 nM)。 | |||
T11020 |
DHODH-IN-11
|
Dehydrogenase; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
DHODH-IN-11 是一种来氟米特衍生物和弱二氢乳清酸脱氢酶 (DHODH) 抑制剂,pKa 为 5.03 | |||
T14501 |
BAY-2402234
|
Dehydrogenase; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
BAY-2402234 是一种选择性二氢乳清酸脱氢酶的抑制剂,可研究骨髓恶性肿瘤。 | |||
T9394 |
CHIKV-IN-2
|
Dehydrogenase | Metabolism |
CHIKV-IN-2 基孔肯雅病毒的选择性抑制剂,具有强大的细胞抗病毒活性 (EC90=270 nM) 以及能够改善肝微粒体稳定性。它能够抑制细胞靶二氢乳清酸脱氢酶的活性。 | |||
T8767 |
PfDHODH-IN-2
|
Dehydrogenase; Parasite | Metabolism; Microbiology/Virology |
PfDHODH-IN-2 是一种二氢噻吩酮衍生物,是一种有效的恶性疟原虫二氢乳清酸脱氢酶抑制剂,其IC50值为 1.11 µM。它具有抗疟作用,可研究疟疾。 | |||
T2601 |
Vidofludimus
SC12267,4sc-101 |
Dehydrogenase; DNA/RNA Synthesis; Interleukin | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Immunology/Inflammation; Metabolism |
Vidofludimus (SC12267) 是一种新型的二氢乳清酸脱氢酶 (DHODH) 小分子抑制剂,可在不影响淋巴细胞增殖的条件下抑制IL-17的分泌。 | |||
T9121 |
AG-636
|
Dehydrogenase; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
AG-636 是一种选择性可逆和具有口服活性的二氢乳清酸脱氢酶(DHODH)抑制剂,IC50 为 17 nM,具有很强的抗癌作用。 | |||
T13774 |
ML390
|
Others; Dehydrogenase | Metabolism; Others |
ML390 是二氢乳清酸脱氢酶抑制剂。他是骨髓分化的诱导剂,能够引起鼠 (ER-HoxA9) 以及人 (U937 and THP1) 急性髓细胞性白血病 (AML) 细胞发生骨髓分化。 | |||
T1919 |
Tenovin-1
Tenovin 1 |
Mdm2; Dehydrogenase; Sirtuin; p53; Autophagy | Apoptosis; Autophagy; Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism |
Tenovin-1 抑制 SirT1 和 SirT2 的蛋白质去乙酰化活性,并防止 MDM2 介导的 p53 降解,这涉及泛素化。它具有癌症的研究潜力。 | |||
T1818 |
Tenovin-6
Tenovin 6 |
Dehydrogenase; Sirtuin; Autophagy | Autophagy; Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism |
Tenovin-6 是 Tenovin-1 的类似物,能抑制二氢乳清酸脱氢酶。它也抑制纯化人 SIRT1、SIRT2 和 SIRT3 蛋白脱乙酰酶活性,IC50分别为 21 μM、10 μM 和 67 μM。它是一种 p53转录活性的激活剂。 | |||
T8480 |
Tenovin-6 Hydrochloride
|
Dehydrogenase; Sirtuin; HDAC; p53; Autophagy | Apoptosis; Autophagy; Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism |
Tenovin-6 Hydrochloride 是 Tenovin-1 的类似物,能抑制二氢乳清酸脱氢酶。它是一种 p53转录活性的激活剂,抑制纯化人 SIRT1、SIRT2 和 SIRT3 蛋白脱乙酰酶活性,IC50分别为 21 μM、10 μM 和 67 μM。 | |||
T5013 |
Brequinar
Bipenquinate,NSC 368390,DUP785,布喹那 |
Virus Protease; Dehydrogenase; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism; Microbiology/Virology |
Brequinar (NSC-368390) 是二氢乳清酸脱氢酶的一种强效抑制剂,对广谱病毒具有强效活性。 | |||
T1159 |
Leflunomide
SU101,RS-34821,HWA486,来氟米特 |
Others; Dehydrogenase; AhR | Immunology/Inflammation; Metabolism; Others |
Leflunomide (HWA486) 是嘧啶合成抑制剂,能够抑制二氢乳清酸脱氢酶,具有抗风湿的活性。 | |||
T10384 |
Farudodstat
ASLAN003 |
Apoptosis; Dehydrogenase; DNA/RNA Synthesis | Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism |
Farudodstat (ASLAN003) 是一种具有口服活性的二氢乳清酸脱氢酶 (DHODH) 抑制剂,对人 DHODH 酶的IC50为 35 nM。它通过激活 AP-1 转录因子来抑制蛋白质合成,可以诱导凋亡,并在急性髓样白血病异种移植小鼠中大大延长其生存期。 | |||
T12574 |
PTC299
Emvododstat,(4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate |
VEGFR; Dehydrogenase | Angiogenesis; Metabolism; Tyrosine Kinase/Adaptors |
PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) 是一种口服活性的 VEGFA mRNA 翻译抑制剂,可选择性地抑制转录后水平的 VEGF 蛋白合成。它还是二氢乳酸脱氢酶 (DHODH) 的有效抑制剂,可研究血液系统恶性肿瘤。 | |||
T11019 |
DHODH-IN-1
|
Dehydrogenase | Metabolism |
DHODH-IN-1 是一种有效的 DHODH 抑制剂 (IC50 = 25 nM) 并抑制嘧啶生物合成途径。 | |||
T11024 |
DHODH-IN-15
|
Dehydrogenase | Metabolism |
DHODH-IN-15是一种 A771726 的 hydroxyfurazan 类似物。DHODH-IN-15 是一种二氢乳清酸脱氢酶 (DHODH) 抑制剂,对大鼠肝脏 DHODH 的 IC50 为 11 μM。DHODH-IN-15 可用于类风湿关节炎。 | |||
T11030 |
DHODH-IN-8
|
Dehydrogenase | Metabolism |
DHODH-IN-8 是一种人和恶性疟原虫二氢乳清酸脱氢酶的抑制剂,IC50 分别为 0.13 μM 和 47.4 μM,Ki 分别为 0.016 μM 和 5.6 μM。DHODH-IN-8 具有抗疟疾能力。 | |||
T8332 |
Bipenquinate
|
Dehydrogenase | Metabolism |
Bipenquinate 是一种有效的、选择性的二氢乳清酸脱氢酶 (DHODH) 抑制剂,IC50 为 20 nM,阻断嘧啶的从头生物合成。 | |||
T11023 |
DHODH-IN-14
|
Dehydrogenase | Metabolism |
DHODH-IN-14是一种 A771726 的 hydroxyfurazan 类似物。DHODH-IN-14 是一种二氢乳清酸脱氢酶 (DHODH) 抑制剂,对大鼠肝脏 DHODH 的 IC50 为 0.49 μM。DHODH-IN-14 可用于类风湿关节炎。 | |||
T11027 |
DHODH-IN-4
|
Dehydrogenase | Metabolism |
DHODH-IN-4 是人和 Plasmodium falciparum 二氢乳清酸脱氢酶 (DHODH) 的抑制剂,其对 PfDHODH 和 HsDHODH 的IC50 值分别为 4 μM 和 0.18 μM。DHODH-IN-4 (compound 17) 具有抗疟疾活性。 | |||
T40087 |
DSM502
|
||
DSM502, a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor, demonstrates potent nanomolar activity against Plasmodium DHODH and Plasmodium parasites, while not inhibiting mammalian DHODHs. | |||
T26900 |
BRD7539
BRD-7539,BRD 7539 |
||
BRD7539B is a Dihydroorotate dehydrogenase (DHODH) inhibitor . RD7539 shows to target PfDHODH (IC50 = 0.033 μM) selectively over human (Hs) DHODH (IC50 > 50 μM). | |||
T71865 | DSM43 | ||
DSM43 is a dihydroorotate dehydrogenase (DHODH) inhibitor. Malaria puts at risk nearly half the world's population and causes high mortality in sub-Saharan Africa, while drug resistance threatens current therapies. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) is a validated target for malaria treatmen | |||
T11026 |
DHODH-IN-3
|
Others | Others |
DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria. | |||
T27498 |
GSK983
GSK-983,GSK 983 |
||
GSK983, a potent broad-spectrum antiviral, blocks cell proliferation and dengue virus replication by inhibiting the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH). | |||
T14780 | BRD9185 | Dehydrogenase | Metabolism |
BRD9185 is an inhibitor of Dihydroorotate dehydrogenase (DHODH) with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro. | |||
T40291 |
DSM705
DSM705 |
||
DSM705 is a pyrrole-based inhibitor of Dihydroorotate Dehydrogenase (DHODH). It demonstrates high potency in the nanomolar range against Plasmodium DHODH and Plasmodium parasites, while not interfering with mammalian DHODHs. DSM705 shows significant efficacy as an antimalarial compound. | |||
T60409 |
P1788
|
||
P1788 是一种二氢乳清酸脱氢酶 (DHODH) 抑制剂,可诱导 DNA 损伤。 | |||
T62550 | DSM705 hydrochloride | ||
DSM705 hydrochloride 是一种有效的抗疟化合物,是一种基于吡咯的二氢乳清酸脱氢酶 (DHODH) 抑制剂。DSM705 hydrochloride 对 PlasmodiumDHODH 和 Plasmodium 寄生虫显示出纳摩尔级作用,不抑制哺乳动物 DHODH。 | |||
T11813 |
Laflunimus
HR325 |
Others | Others |
Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). | |||
T78932 |
hDHODH-IN-12
|
DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
hDHODH-IN-12是一种有效的DHODH抑制剂,IC50值为0.421 μM,DHODH作为嘧啶从头合成的限速酶,在(DNA/RNA Synthesis)DNA与RNA生成中扮演重要角色。hDHODH-IN-12位于人类线粒体内膜,展示了研究肺癌的潜力。 | |||
T70899 |
Vidofludimus hemicalcium
4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium |
||
Vidofludimus (4sc-101 ; SC12267) hemicalcium 是一种口服有效的二氢乳清酸脱氢酶 (DHODH) 的抑制剂,也是法尼醇 X 受体 (FXR) 调节剂。Vidofludimus hemicalcium 作为一种免疫调节剂,可用于研究自身免疫性疾病,如炎症性肠病 (IBD)。Vidofludimus hemicalcium 还可通过靶向FXR 用于脂肪肝的研究。 | |||
T72696 |
UCK2 Inhibitor-3
|
||
UCK2 Inhibitor-3是一款UCK2 (尿苷胞苷激酶2)的非竞争性抑制剂,其IC50值为16.6 μM。该化合物能在一定程度上补偿因感染或快速分裂的细胞中DHODH (二氢旋酸脱氢酶)功能的缺失,有效地挽救尿苷。此外,UCK2 Inhibitor-3还能抑制DNA聚合酶η和κ,其IC50值分别为56 μM和16 μM。 |